Your transplant team watches for several recognized complications after heart transplant — knowing what they are, how they're caught, and how they're treated can make the surveillance schedule behind Monitoring, Procedures & Labs After Transplant feel a lot less abstract, and helps you understand why your team responds the way it does to a given test result.
Rejection
Acute rejection can happen at any time but is more common in the first year. Detected through routine surveillance endomyocardial biopsies (the gold standard) and, increasingly at some centers, non-invasive blood-based rejection surveillance (see HeartCare Panel: AlloMap & AlloSure) — often before you'd feel anything at all. Managed with adjustments to your immunosuppression regimen, tailored to how significant the rejection is: a minor, temporary dose increase for mild rejection, up through more intensive treatment (sometimes including a short hospital stay for IV therapy) for higher-grade rejection.
Chronic rejection / cardiac allograft vasculopathy (CAV) is a slower, longer-term, diffuse narrowing of the transplanted heart's blood vessels — functionally similar in effect to coronary artery disease but affecting the vessels more broadly, which is part of why it can be harder to treat with the same catheter-based tools used for typical coronary blockages. Detected through periodic coronary angiography or intravascular ultrasound, sometimes stress testing (see Cardiac Testing & Imaging). Managed through statin therapy (which has a specific, additional anti-CAV benefit in transplant patients beyond cholesterol-lowering alone — one reason statins are essentially universal in transplant regimens), general cardiovascular risk-factor control, catheter-based or surgical options in select cases, and, if severe, evaluation for re-transplant.
Infection
Your intentionally suppressed immune system means infections that would be minor for others can become more serious for you. Detected through prompt evaluation of fever, localized symptoms (cough, urinary symptoms, wound changes), or simply "not feeling right" — a low threshold for calling your team is the point, not an overreaction. Certain infections, particularly CMV, warrant their own dedicated attention (see CMV Disease & Monitoring After Transplant), which is exactly why prevention starts before symptoms ever appear (see Post-Transplant Antimicrobial Prophylaxis). Managed with targeted treatment once identified, sometimes alongside a temporary adjustment to your immunosuppression to let your immune system help fight the infection — balanced carefully against rejection risk, a genuine clinical tightrope your transplant team is specifically trained to navigate.
Kidney Dysfunction
Calcineurin inhibitors (tacrolimus, cyclosporine) are effective anti-rejection medications, but they can affect kidney function over years of use, since they directly affect blood flow within the kidney's own small vessels. Detected through routine blood tests tracking kidney function at every follow-up visit. Managed through dose adjustments, sometimes shifting more of your regimen's weight onto other medication classes to reduce calcineurin-inhibitor exposure, and standard kidney-protective measures — blood pressure control, avoiding NSAIDs. (See Medications & Substances to Avoid with Heart Disease.)
Malignancy
Long-term immunosuppression raises the risk of certain cancers, particularly skin cancer and a specific lymphoma associated with immunosuppression (PTLD, post-transplant lymphoproliferative disorder). Detected through routine age-appropriate cancer screening plus specific attention to skin checks and any new lumps, weight loss, or unexplained symptoms. Managed according to the specific cancer type, often in coordination between your transplant team and oncology, sometimes including a temporary, carefully considered reduction in immunosuppression intensity as part of treatment.
Why Your Team Balances Rejection Risk Against Everything Else
Nearly every complication above shares a common thread: treating it often means adjusting the exact medications that are protecting your heart from rejection. This is the central, ongoing balancing act of post-transplant care — enough immunosuppression to protect your new heart, not so much that infection, kidney injury, or cancer risk climbs unnecessarily. It's exactly why your transplant team, not general guidance like this page, makes these specific tradeoffs for you, informed by your individual test results and history.
Common Questions
Which complication is most common?
Acute rejection risk is highest in the first year, while infection risk tracks closely with how intensively immunosuppressed you are at any given time — both are actively monitored for from day one.
If I develop a complication, does that mean my transplant failed?
No — these are recognized, expected possibilities that transplant teams are specifically trained to catch early and manage; most are treatable, especially when caught through routine surveillance before symptoms develop.
Can these complications be prevented entirely?
Not entirely, but risk is meaningfully reduced through consistent medication adherence, the preventive medications and vaccination guidance your team provides, routine monitoring, and prompt reporting of new symptoms.
How do I know if my medication adjustment is because of rejection or something else?
Ask your team directly — they can explain exactly which result prompted the change and what it means for your specific situation, since the same class of adjustment can be used for different reasons.